Manchester Cancer Research Centre Building,
Department Cancer Sciences,
Manchester Cancer Research Centre Building, Department Cancer Sciences
David E. Gilham has not added Biography.
If you are David E. Gilham and would like to personalize this page please email our Author Liaison for assistance.
Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.
Journal of immunotherapy (Hagerstown, Md. : 1997) Mar-Apr, 2002 | Pubmed ID: 12074044
Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases.
Diseases of the colon and rectum Jun, 2003 | Pubmed ID: 12794582
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) May-Jun, 2005 | Pubmed ID: 15838376
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
British journal of haematology May, 2005 | Pubmed ID: 15842655
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.
Journal of immunology (Baltimore, Md. : 1950) Oct, 2006 | Pubmed ID: 16982863
Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK.
Cancer immunology, immunotherapy : CII Jun, 2007 | Pubmed ID: 17333180
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Cancer immunology, immunotherapy : CII May, 2008 | Pubmed ID: 17899077
Eotaxin-2 and colorectal cancer: a potential target for immune therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research Oct, 2007 | Pubmed ID: 17908961
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.
British medical bulletin , 2008 | Pubmed ID: 18245773
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.
British journal of haematology Jul, 2008 | Pubmed ID: 18477047
The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy.
Cancer immunology, immunotherapy : CII Jun, 2010 | Pubmed ID: 19669146
Cytokine stimulation and the choice of promoter are critical factors for the efficient transduction of mouse T cells with HIV-1 vectors.
The journal of gene medicine Feb, 2010 | Pubmed ID: 20033928
Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis.
Cytometry. Part A : the journal of the International Society for Analytical Cytology Apr, 2010 | Pubmed ID: 20033991
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
Journal of immunology (Baltimore, Md. : 1950) Feb, 2010 | Pubmed ID: 20089697
Development of adoptive cell therapy for cancer: a clinical perspective.
Human gene therapy Jun, 2010 | Pubmed ID: 20408760
Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent.
Human gene therapy Nov, 2010 | Pubmed ID: 20528679
Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.
Molecular therapy : the journal of the American Society of Gene Therapy Dec, 2010 | Pubmed ID: 20736928
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.
Cancer immunology, immunotherapy : CII Jul, 2012 | Pubmed ID: 22127365
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Cancer immunology, immunotherapy : CII Jul, 2012 | Pubmed ID: 22527245
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Trends in molecular medicine Jul, 2012 | Pubmed ID: 22613370
Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?
Breast cancer research : BCR May, 2012 | Pubmed ID: 22643384
Chimeric antigen receptors for T-cell based therapy.
Methods in molecular biology (Clifton, N.J.) , 2012 | Pubmed ID: 22907378
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.
Human gene therapy methods Oct, 2013 | Pubmed ID: 23931270
Targeting T cells to tumor: exploiting the chimeric antibody receptor.
Immunotherapy Sep, 2013 | Pubmed ID: 23998728
Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol.
Human gene therapy methods Dec, 2013 | Pubmed ID: 24028672
CAR T cells: driving the road from the laboratory to the clinic.
Immunological reviews Jan, 2014 | Pubmed ID: 24329792
Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.
Journal of immunology (Baltimore, Md. : 1950) Apr, 2014 | Pubmed ID: 24623129
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
Cancer immunology, immunotherapy : CII Nov, 2017 | Pubmed ID: 28660319
Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) Apr, 2018 | Pubmed ID: 29239915
Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Cancer immunology, immunotherapy : CII Oct, 2018 | Pubmed ID: 30039427
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。